Financials NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
29.72 ^USD	+3.73%		-2.59%	+99.06%

Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	MT

Projected Income Statement: NovoCure Limited

income-statement-evolution-chart NOVOCURE-LIMITED

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	351.3	494.4	535	537.8	509.3	597	626.5	691.1
Change	-	40.72%	8.23%	0.53%	-5.3%	17.2%	4.96%	10.31%
EBITDA ¹	7.546	39.55	-34.08	-78.9	-221.9	-142.9	-172.2	-154.7
Change	-	424.13%	-	131.5%	181.25%	35.58%	-20.49%	10.19%
EBIT ¹	-0.914	30.4	-44.33	-89.52	-232.9	-151.3	-179.4	-175.4
Change	-	-	-	101.93%	160.12%	35.03%	-18.6%	2.23%
Interest Paid	-7.91	-12.3	-7.742	7.677	-	-	-	-5
Earnings before Tax (EBT) ¹	-8.824	18.1	-52.08	-81.85	-191.7	-110	-156.3	-156.6
Change	-	-	-	57.17%	134.27%	42.62%	-42.08%	-0.17%
Net income ¹	-7.23	19.81	-58.35	-92.53	-207	-142.2	-164.1	-159.5
Change	-	-	-	58.58%	123.75%	31.33%	-15.43%	2.82%
Announcement Date	2/27/20	2/25/21	2/24/22	2/23/23	2/22/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	99.23	101.8	115.9	132.7	144	134.7	133.5	133.6	133.2	137.5	140.9	131	128.4	122.2	126.1	127.3	133.8	138.5	150.4	155.1	153	155	156.9	159.6	162
Change	-	2.61%	13.84%	14.44%	8.51%	-6.43%	-0.87%	0.07%	-0.29%	3.25%	2.41%	-7.01%	-1.96%	-4.86%	3.17%	1.01%	5.08%	3.53%	8.56%	3.15%	-1.32%	1.27%	1.21%	1.72%	1.54%
EBITDA ¹	2.619	-1.493	9.269	17.21	14.56	2.282	-9.815	-5.818	-20.73	1.804	-18.47	-21.95	-40.28	-57.53	-59.94	-55.44	-48.99	-38.7	-30.72	-29.63	-43.24	-43.43	-42.64	-37.27	-43.47
Change	-	-	-	85.67%	-15.37%	-84.33%	-	-40.72%	256.33%	-	-	18.83%	83.48%	42.82%	4.19%	-7.5%	-11.63%	-21%	-20.63%	-3.54%	-45.91%	-0.44%	1.81%	12.6%	-16.63%
EBIT ¹	0.152	-3.381	6.668	15.02	12.09	-0.088	-12.3	-8.552	-23.4	-0.806	-21.13	-24.61	-42.98	-60.25	-62.66	-58.24	-51.72	-41.52	-33.58	-32.09	-44.06	-45.99	-45.25	-39.93	-46.17
Change	-	-	-	125.28%	-19.5%	-	13,871.59%	-30.44%	173.6%	-96.56%	2,521.34%	16.49%	74.63%	40.19%	4%	-7.05%	-11.21%	-19.72%	-19.12%	-4.43%	-37.28%	-4.38%	1.6%	11.76%	-15.65%
Charge d'intérêts	-1.744	-2.432	-2.617	-3.983	-3.267	-2.646	-0.94	-1.981	-2.175	-1.709	-2.228	1.194	10.42	-	-	-	-	-	-	-	-	-	-	-	-
Earnings before Tax (EBT) ¹	-1.592	-5.813	4.051	11.04	8.825	-2.734	-13.24	-10.53	-25.57	-2.515	-23.36	-23.42	-32.56	-51.08	-53.9	-48.22	-38.53	-31.64	-22.73	-21.58	-33.96	-36.98	-36.24	-31.42	-37.67
Change	-	265.14%	-	172.5%	-20.06%	-	384.09%	-20.42%	142.79%	-90.17%	828.67%	0.26%	39.04%	56.89%	5.53%	-10.54%	-20.09%	-17.89%	-28.17%	-5.03%	-57.31%	-8.91%	2%	13.31%	-19.88%
Net income ¹	4.26	3.952	1.655	9.284	4.917	-4.128	-14.64	-13.12	-26.46	-4.647	-24.01	-26.58	-37.3	-53.06	-57.42	-49.48	-47.08	-38.76	-33.38	-30.57	-39.51	-44.98	-44.24	-39.42	-45.67
Change	-	-7.23%	-58.12%	460.97%	-47.04%	-	254.68%	-10.36%	101.6%	-82.44%	416.63%	10.7%	40.36%	42.24%	8.21%	-13.82%	-4.86%	-17.67%	-13.89%	-8.4%	-29.26%	-13.84%	1.64%	10.9%	-15.85%
Announcement Date	2/27/20	4/30/20	7/30/20	10/29/20	2/25/21	4/29/21	7/29/21	10/28/21	2/24/22	4/28/22	7/28/22	10/27/22	2/23/23	5/4/23	7/27/23	10/26/23	2/22/24	5/2/24	7/25/24	10/30/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: NovoCure Limited

balance-sheet-analysis-chart NOVOCURE-LIMITED

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-27.9	195	353	450	328	-179	-40.9	-114
Change	-	598.92%	81.03%	27.48%	-27.11%	-154.57%	-122.85%	-378.73%
Announcement Date	2/27/20	2/25/21	2/24/22	2/23/23	2/22/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: NovoCure Limited

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	10.48	14.97	24.17	21.36	27.09	25	36	60
Change	-	42.76%	61.48%	-11.63%	26.85%	-7.73%	44%	66.67%
Free Cash Flow (FCF) ¹	16.14	84.18	58.59	9.43	-100.4	-253.9	-66.5	-128
Change	-	421.72%	-30.4%	-83.9%	-1,164.99%	152.82%	-73.81%	92.48%
Announcement Date	2/27/20	2/25/21	2/24/22	2/23/23	2/22/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: NovoCure Limited

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	2.15%	8%	-6.37%	-14.67%	-43.57%	-23.95%	-27.49%	-22.38%
EBIT Margin (%)	-0.26%	6.15%	-8.29%	-16.64%	-45.72%	-25.35%	-28.64%	-25.38%
EBT Margin (%)	-2.51%	3.66%	-9.73%	-15.22%	-37.64%	-18.43%	-24.95%	-22.66%
Net margin (%)	-2.06%	4.01%	-10.91%	-17.2%	-40.65%	-23.82%	-26.19%	-23.08%
FCF margin (%)	4.59%	17.03%	10.95%	1.75%	-19.72%	-42.53%	-10.61%	-18.52%
FCF / Net Income (%)	-223.17%	424.98%	-100.4%	-10.19%	48.51%	178.58%	40.52%	80.26%
Profitability
ROA	-1.77%	2.59%	-5.33%	-7.94%	-17.71%	-15.01%	-26.82%	-27.76%
ROE	-4.38%	5.71%	-13.16%	-21.73%	-51.52%	-37.59%	-48.75%	-69.79%
Financial Health
Leverage (Debt/EBITDA)	-	4.94x	-10.37x	-5.71x	-1.48x	-	-	-
Debt / Free cash flow	-	2.32x	6.03x	47.74x	-3.27x	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	2.98%	3.03%	4.52%	3.97%	5.32%	4.19%	5.75%	8.68%
CAPEX / EBITDA (%)	138.95%	37.84%	-70.92%	-27.07%	-12.21%	-17.49%	-20.9%	-38.79%
CAPEX / FCF (%)	64.98%	17.78%	41.26%	226.49%	-26.98%	-9.85%	-54.14%	-46.88%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	2.188	4.657	3.948	-	-	-	-	-
Change	-	112.8%	-15.21%	-	-	-	-	-
EPS ¹	-0.07	0.2	-0.56	-0.88	-1.95	-1.315	-1.541	-1.48
Change	-	-385.71%	-380%	57.14%	121.59%	-32.57%	17.22%	-4%
Nbr of stocks (in thousands)	98,969	101,797	103,819	104,950	106,861	108,201	108,201	108,201
Announcement Date	2/27/20	2/25/21	2/24/22	2/23/23	2/22/24	-	-	-